HK Stock Movement | ASCLETIS-B (01672) Surges Over 7% in Late Trading as ASC36 Enters Clinical Development Phase, IND Application to Be Submitted in Q2 Next Year

Stock News

Nov 11

ASCLETIS-B (01672) surged over 7% in late trading, closing up 7.05% at HK$11.08 with a turnover of HK$59.94 million. The company recently announced the selection of ASC36, a potential "best-in-class" once-monthly subcutaneous amylin receptor agonist, as a clinical development candidate. ASCLETIS-B plans to submit an Investigational New Drug (IND) application to the U.S. FDA for ASC36 in the treatment of obesity in Q2 2026.

ASC36 is a peptide-based amylin receptor agonist developed by ASCLETIS, optimized for extended apparent half-life and higher bioavailability per milligram, enabling once-monthly subcutaneous dosing. Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS-B, stated that preclinical data suggest ASC36 could achieve best-in-class efficacy with monthly dosing, potentially offering superior weight loss benefits and a simpler, patient-friendly titration regimen.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1155120703"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1155120703\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1155120703?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 15:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155120703","market":"sh","top_or_hot":-1,"title":"HK Stock Movement | ASCLETIS-B (01672) Surges Over 7% in Late Trading as ASC36 Enters Clinical Development Phase, IND Application to Be Submitted in Q2 Next Year","media":"Stock News","content":"<p>ASCLETIS-B (01672) surged over 7% in late trading, closing up 7.05% at HK$11.08 with a turnover of HK$59.94 million. The company recently announced the selection of ASC36, a potential \"best-in-class\" once-monthly subcutaneous amylin receptor agonist, as a clinical development candidate. ASCLETIS-B plans to submit an Investigational New Drug (IND) application to the U.S. FDA for ASC36 in the treatment of obesity in Q2 2026.</p>\n<p>ASC36 is a peptide-based amylin receptor agonist developed by ASCLETIS, optimized for extended apparent half-life and higher bioavailability per milligram, enabling once-monthly subcutaneous dosing. Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS-B, stated that preclinical data suggest ASC36 could achieve best-in-class efficacy with monthly dosing, potentially offering superior weight loss benefits and a simpler, patient-friendly titration regimen.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | ASCLETIS-B (01672) Surges Over 7% in Late Trading as ASC36 Enters Clinical Development Phase, IND Application to Be Submitted in Q2 Next Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | ASCLETIS-B (01672) Surges Over 7% in Late Trading as ASC36 Enters Clinical Development Phase, IND Application to Be Submitted in Q2 Next Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-11 15:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ASCLETIS-B (01672) surged over 7% in late trading, closing up 7.05% at HK$11.08 with a turnover of HK$59.94 million. The company recently announced the selection of ASC36, a potential \"best-in-class\" once-monthly subcutaneous amylin receptor agonist, as a clinical development candidate. ASCLETIS-B plans to submit an Investigational New Drug (IND) application to the U.S. FDA for ASC36 in the treatment of obesity in Q2 2026.</p>\n<p>ASC36 is a peptide-based amylin receptor agonist developed by ASCLETIS, optimized for extended apparent half-life and higher bioavailability per milligram, enabling once-monthly subcutaneous dosing. Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS-B, stated that preclinical data suggest ASC36 could achieve best-in-class efficacy with monthly dosing, potentially offering superior weight loss benefits and a simpler, patient-friendly titration regimen.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01672","symbol_name":"歌礼制药-B","start_time":0,"source_url":"","article_id":"1155120703","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155120703","pubTimestamp":1762845854,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ASCLETIS-B (01672) surged over 7% in late trading, closing up 7.05% at HK$11.08 with a turnover of HK$59.94 million. The company recently announced the selection of ASC36, a potential \"best-in-class\"...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01672":"歌礼制药-B","LU2153591404.USD":"Aberdeen Standard SICAV I - Asian Sustainable Development Equity A Acc USD","LU0572939691.SGD":"Janus Henderson Horizon Asian Dividend Income A2 SGD","LU1211504680.USD":"ALLIANZ HIGH DIVIDEND ASIA PACIFIC EQUITY \"AM\" (USD) INC","LU1316543674.SGD":"Janus Henderson Horizon Asia-Pacific Property Income A3 SGD","01477":"欧康维视生物-B","BK1229":"房地产经营公司","LU0149534421.HKD":"SCHRODER ISF HONG KONG EQ \"A\" ACC","BK1191":"制药","BK1161":"生物科技","BK1258":"房地产运营公司","LU0572940350.SGD":"Janus Henderson Horizon Asian Dividend Income A3 SGD","LU2226123227.USD":"Janus Henderson Horizon Asia-Pacific Property Income A5m USD","LU0607220059.USD":"SCHRODER ISF HONG KONG EQUITY \"A\" (USD) ACC","BK1601":"香港本地股","LU2226123490.SGD":"Janus Henderson Horizon Asia-Pacific Property Income A5m SGD","BK1515":"抗疫概念","LU2348773727.SGD":"Aberdeen Standard SICAV I - Asian Sustainable Development Equity A Acc SGD-H","LU0229494975.USD":"骏利亨德森亚太地产股票基金","01972":"太古地产","BK1574":"生物医药B类股","BK1534":"收租股","LU0264606111.USD":"Janus Henderson Horizon Asian Dividend Income A2 USD"},"translate_title":"港股动向|歌礼-B(01672)尾盘大涨超7%ASC36进入临床开发阶段明年Q2递交IND申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"01672":1,"01972":1},"content_text":"ASCLETIS-B (01672) surged over 7% in late trading, closing up 7.05% at HK$11.08 with a turnover of HK$59.94 million. The company recently announced the selection of ASC36, a potential \"best-in-class\" once-monthly subcutaneous amylin receptor agonist, as a clinical development candidate. ASCLETIS-B plans to submit an Investigational New Drug (IND) application to the U.S. FDA for ASC36 in the treatment of obesity in Q2 2026.\nASC36 is a peptide-based amylin receptor agonist developed by ASCLETIS, optimized for extended apparent half-life and higher bioavailability per milligram, enabling once-monthly subcutaneous dosing. Dr. Jinzi Wu, Founder, Chairman, and CEO of ASCLETIS-B, stated that preclinical data suggest ASC36 could achieve best-in-class efficacy with monthly dosing, potentially offering superior weight loss benefits and a simpler, patient-friendly titration regimen.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}